Evidence map›Paper›PMID 33643218›Full record

ArticleFrontiers in endocrinology2020

The Ablation of Thyroid Nodule's Afferent Arteries Before Radiofrequency Ablation: Preliminary Data.

Chiara Offi, Sara Garberoglio, Giovanni Antonelli, Maria Grazia Esposito, Umberto Brancaccio, Claudia Misso, Edoardo D'Ambrosio, Daniela Pace, Stefano Spiezia

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. [Clinical Approach for Thyroid Radiofrequency Ablation].Journal of the Korean Society of Radiology · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Chiara OffiDepartment of Endocrine and Ultrasound-guided Surgery, "Ospedale del Mare", Naples, Italy.
Sara GarberoglioDivision of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Giovanni AntonelliDepartment of Endocrine and Ultrasound-guided Surgery, "Ospedale del Mare", Naples, Italy.
Maria Grazia EspositoDepartment of Endocrine and Ultrasound-guided Surgery, "Ospedale del Mare", Naples, Italy.
Umberto BrancaccioDepartment of Endocrine and Ultrasound-guided Surgery, "Ospedale del Mare", Naples, Italy.
Claudia MissoDepartment of Endocrine and Ultrasound-guided Surgery, "Ospedale del Mare", Naples, Italy.
Edoardo D'AmbrosioDepartment of Endocrine and Ultrasound-guided Surgery, "Ospedale del Mare", Naples, Italy.
Daniela PaceDepartment of Endocrinology, Valmontone Hospital, Valmontone, Italy.
Stefano SpieziaDepartment of Endocrine and Ultrasound-guided Surgery, "Ospedale del Mare", Naples, Italy.
Ospedale D. Cotugno · ITUniversity of Turin · ITValmontone Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Induced radiofrequency thermal ablation is the cytoreductive treatment of symptomatic benign thyroid nodules, metastatic and recurrent thyroid tumors and papillary thyroid microcarcinomas. It is a safe and effective alternative to surgery and it allows to obtain satisfactory results in terms of volumetric reduction of the nodule with significant improvement in the quality of life. The trans-isthmic approach and the moving shot technique are the two basic techniques; however, an advanced technique, artery-first feeding radiofrequency ablation, has been developed and validated. We have prospectively included 29 consecutive patients who have undergone radiofrequency ablation (Group A) or artery- first vRFA (Group B). All included patients had a diagnosis of benign nodular goiter and they underwent a single session of radiofrequency ablation. All patients followed a follow-up program at 1 month, 3 months, and 6 months. Continuous variables (age, TSH value, basal volume of nodule, used Joule, time in second of the procedure, nodules' volume at 1-, 3-, and 6- months of follow-up and percentage of volume reduction at 1-, 3-, and 6- months of follow-up) were described as mean, standard deviation and range, while categorical variables (gender, nodule structure and nodule vascularization) were described as number of cases and percentage. Independent samples t-test were performed to compare the continuous variables. A Test of Proportions was applied to the categorical variables. The Fisher's exact test was used to analyze the gender. Statistical significance was considered in case of p-value <0.05. Solid structure and spongiform structure showed statistic differences with p-values of 0.022 and 0.023 respectively between two groups. The percentage of reduction at 1 month did not show a significant difference between two groups; instead, the percentage of volume reduction was decreased mostly in the Group B at 3 months and 6 months of follow-up with a p-value of 0.003 and 0.013, respectively. The Joules/energy used showed a statistically significant difference (p-value=0.05), more energy must be used in vascular radiofrequency ablation. These data allow us to hypothesize that vRFA may improve the effectiveness of the procedure, allowing for a reduction in volume more quickly. They were preliminary but promising results, clearly a larger series of cases and prolonged follow-up are needed to clarify and confirm our observations.

Indexed as

AdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesRadiofrequency AblationThyroid NoduleTreatment Outcomeradiofrequency ablationtechniquethermal ablationthyroid nodulesultrasound

Identifiers

PMID33643218
PMCPMC7906008
OpenAlexW3129272580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.